Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression
Depression is among the most common mental health disorders worldwide and treatment resistant depression (TRD) represents a major challenge for both patients and clinicians. In recent years ketamine has received attention as an antidepressant agent, demonstrating promising results in TRD in adults....
Main Authors: | Katrin Skala, Kamer Doganay, Harald Eder, Dunja Mairhofer, Katrin Neubacher, Paul L. Plener |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-06-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1118737/full |
Similar Items
-
Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
by: Johanna Louise Keeler, et al.
Published: (2023-05-01) -
The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
by: Ludivine Boudieu, et al.
Published: (2023-12-01) -
Intranasal ketamine versus intranasal fentanyl on pain management in isolated traumatic patients
by: Mehdi Nasr Isfahani, et al.
Published: (2022-01-01) -
The role of intranasal esketamine in treatment-resistant depression
by: A. Fraga, et al.
Published: (2021-04-01) -
Efficacy and safety of intranasal midazolam versus intranasal ketamine as sedative premedication in pediatric patients: a meta-analysis of randomized controlled trials
by: Bingchen Lang, et al.
Published: (2022-12-01)